The ethanol extract of Zingiber zerumbet rhizomes mitigates vascular lesions in the diabetic retina

Vascular Pharmacology

Volumn 76, Issue , 2015, Pages 18-27

  Hong, Tang Yao ^a   Tzeng, Thing Fong ^a   Liou, Shorong Shii ^a   Liu, I Min ^a  

^a TAJEN UNIVERSITY   (Taiwan)

Author keywords

Diabetic retinopathy; NF B; PEDF; VEGF; Zingiber zerumbet rhizomes

Indexed keywords

ALCOHOL; DOBESILATE CALCIUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PIGMENT EPITHELIUM DERIVED FACTOR; PLANT EXTRACT; STREPTOZOCIN; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ZINGIBER ZERUMBET EXTRACT; EYE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD EYE BARRIER; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC MACULAR EDEMA; DRUG EFFECT; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RETINA BLOOD VESSEL; RHIZOME; UPREGULATION; ZINGIBER ZERUMBET; ANIMAL; CHEMISTRY; DIABETIC RETINOPATHY; DIET THERAPY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; RETINA; SIGNAL TRANSDUCTION; WISTAR RAT; ZINGIBERACEAE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ETHANOL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; EYE PROTEINS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MAP KINASE SIGNALING SYSTEM; NERVE GROWTH FACTORS; NF-KAPPA B; PLANT EXTRACTS; RATS; RATS, WISTAR; RETINA; RETINAL VESSELS; RHIZOME; SERPINS; STREPTOZOCIN; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; ZINGIBERACEAE;

EID: 84961154703     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.08.015     Document Type: Article

References (47)

1. N. Cheung, P.Mitchell, T.Y. Wong, Diabetic retinopathy, Lancet 376 (2010) 124-136.
2. D.A. Antonetti, R. Klein, T.W. Gardner, Diabetic retinopathy, N Engl JMed 366 (2012) 1227-1239.
3. C. Rask-Madsen, G.L. King, Vascular complications of diabetes:mechanisms of injury and protective factors, Cell Metab 17 (2013) 20-33.
4. T.K. Mattila, A. de Boer, Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus, Drugs 70 (2010) 2229-2245.
5. J. Tang, T.S. Kern, Inflammation in diabetic retinopathy, Prog Retin Eye Res 30 (2011) 343-358.
6. C. Ostri, M. la Cour, H. Lund-Andersen, Diabetic vitrectomy in a large type 1 diabetes patient population: long-term incidence and risk factors, Acta Ophthalmol 92 (2014) 439-443.
7. P. Romero-Aroca, J. Reyes-Torres, M. Baget-Bernaldiz, C. Blasco-Suñe, Laser treatment for diabetic macular edema in the 21st century, Curr Diabetes Rev 10 (2014) 100-112.
8. S.M. Nalawade, A.P. Sagare, C.Y. Lee, C.L. Kao, H.S. Tsay, Studies on tissue culture of Chinese medicinal plant resources in Taiwan and their sustainable utilization, Bot Bull Aca Sinica 44 (2003) 79-98.
9. R.O. Prakash, A. Rabinarayan, M.S. Kumar, Zingiber zerumbet (L.) Sm., a reservoir plant for therapeutic uses: a review, Int J Pharma World Res 2 (2011) 1-23.
10. N.J. Yob, S.M. Jofrry, M.M. Affandi, L.K. Teh, M.Z. Salleh, Z.A. Zakaria, Zingiber zerumbet (L.) smith: a review of its ethnomedicinal, chemical, and pharmacological uses, Evid Based Complement Alternat Med. 2011 (2011) 543216, http://dx.doi.org/10.1155/2011/543216.
11. I. Jantan, I.A. Rafi, J. Jalil, Platelet-activating factor (PAF) receptor-binding antagonist activity of Malaysian medicinal plants, Phytomedicine 12 (2005) 88-92.
12. S.K. Tan, R. Pippen, Y. Rohana, A.R. Noorsaadah, I. Halijah, K. Norzulaani, Screening of selected zingiberaceae extracts for dengue-2 virus protease inhibitory activities, Sunway Acad J 3 (2006) 1-7.
13. C.J. Chang, T.F. Tzeng, Y.S. Chang, I.M. Liu, Beneficial impact of zingiber zerumbet on insulin sensitivity in fructose-fed rats, Planta Med 78 (2012) 317-325.
14. C.J. Chang, T.F. Tzeng, S.S. Liou, Y.S. Chang, I.M. Liu, Acute and 28-day subchronic oral toxicity of an ethanol extract of zingiber zerumbet (L.) smith in rodents, Evid Based Complement Alternat Med. 2012 (2012) 608284.
15. C.J. Chang, T.F. Tzeng, S.S. Liou, Y.S. Chang, I.M. Liu, Absence of genotoxic and mutagenic effects of zingiber zerumbet (L.) smith (zingiberaceae) extract, Evid Based Complement Alternat Med 2012 (2012) 406296.
16. R. Husen, A.H. Pihie, M. Nallappan, Screening for antihyperglycaemic activity in several local herbs of Malaysia, J Ethnopharmacol 95 (2004) 205-208.
17. T.F. Tzeng, S.S. Liou, C.J. Chang, I.M. Liu, The ethanol extract of zingiber zerumbet attenuates streptozotocin-induced diabetic nephropathy in rats, Evid Based Complement Alternat Med 2013 (2013) 340645.
18. R. Klein, B.E. Klein, S.E. Moss, The Wisconsin epidemiological study of diabetic retinopathy: a review, Diabetes Metab Rev 5 (1989) 559-570.
19. G.L. Wilson, E.H. Leiter, Streptozotocin interactions with pancreatic beta cells and the induction of insulin-dependent diabetes, Curr Top Microbiol Immunol 156 (1990) 27-54.
20. E. Padilla, P. Ganado, M. Sanz, M. Zeini, E. Ruiz, A. Triviño, et al., Calcium dobesilate attenuates vascular injury and the progression of diabetic retinopathy in streptozotocin-induced diabetic rats, Diabetes Metab Res Rev 21 (2005) 132-142.
21. Q. Xu, T. Qaum, A.P. Adamis, Sensitive blood-retinal barrier breakdown quantitation using Evans blue, Invest Ophthalmol Vis Sci 42 (2001) 789-794.
22. R. Russo, F. Cavaliere, G.P. Varano, M. Milanese, A. Adornetto, C. Nucci, et al., Impairment of neuronal glutamate uptake and modulation of the glutamate transporter GLT-1 induced by retinal ischemia, PLoS One 8 (2013), e69250.
23. K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method, Methods 25 (2001) 402-408.
24. C.E. Reiter, X. Wu, L. Sandirasegarane, M. Nakamura, K.A. Gilbert, R.S. Singh, et al., Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin, Diabetes 55 (2006) 1148-1156.
25. H.W. van Dijk, F.D. Verbraak, M. Stehouwer, P.H. Kok, M.K. Garvin, M. Sonka, et al., Association of visual function and ganglion cell layer thickness in patients with diabetes mellitus type 1 and no or minimal diabetic retinopathy, Vision Res 51 (2011) 224-228.
26. A. Junod, L. tAE, I.L. Orc, R. Pictet, A. Gonet, A. Renold, Studies of the diabetogenic action of streptozotocin, Proc Soc Exp Biol Med 126 (1967) 201-205.
27. P. Berthet, J.C. Farine, J.P. Barras, Calcium dobesilate: pharmacological profile related to its use in diabetic retinopathy, Int J Clin Pract 53 (1999) 631-636.
28. R. Madonna, E. Montebello, G. Lazzerini, M. Zurro, R. De Caterina, NA+/H+ exchanger 1-and aquaporin-1-dependent hyperosmolarity changes decrease nitric oxide production and induce VCAM-1 expression in endothelial cells exposed to high glucose, Int J Immunopathol Pharmacol 23 (2010) 755-765.
29. R. Madonna, R. De Caterina, Cellular and molecularmechanisms of vascular injury in diabetes-part II: cellular mechanisms and therapeutic targets, Vascul Pharmacol 54 (2011) 75-79.
30. R. Madonna, R. De Caterina, Aquaporin-1 and sodium-hydrogen exchangers as pharmacological targets in diabetic atherosclerosis, Curr Drug Targets 16 (2015) 361-365.
31. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
32. Y.H. Aldebasi, A.H. Rahmani, A.A. Khan, S.M. Aly, The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy, Int J Clin Exp Med 6 (2013) 239-251.
33. N. Gupta, S.Mansoor, A. Sharma, A. Sapkal, J. Sheth, P. Falatoonzadeh, et al., Diabetic retinopathy and VEGF, Open Ophthalmol J 7 (2013) 4-10.
34. I. Zechmeister-Koss, M. Huic, Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review, Br J Ophthalmol 96 (2012) 167-178.
35. P.M. Titchenell, D.A. Antonetti, Using the past to inform the future: anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathy, Diabetes 62 (2013) 1808-1815.
36. D.W. Dawson, O.V. Volpert, P. Gillis, S.E. Crawford, H. Xu, W. Benedict, et al., Pigment epithelium-derived factor: a potent inhibitor of angiogenesis, Science 285 (1999) 245-258.
37. P.C. Karakousis, S.K. John, K.C. Behling, E.M. Surace, J.E. Smith, A. Hendrickson, et al., Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues, Mol Vis 7 (2001) 154-163.
38. Z. Zheng, H. Chen, G. Ke, Y. Fan, H. Zou, X. Sun, et al., Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathway, Diabetes 58 (2009) 954-964.
39. J. Howlett, M. Ashwell, Glycemic response and health: summary of a workshop, Am J Clin Nutr 87 (2008) 212S-216S.
40. D. Gologorsky, A. Thanos, D. Vavvas, Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy, Mediators Inflamm 2012 (2012) 629452.
41. S. Kaštelan, M. Tomic, A. Gverovic Antunica, J. Salopek Rabatic, S. Ljubic, Inflammation and pharmacological treatment in diabetic retinopathy, Mediators Inflamm 2013 (2013) 213130.
42. Z. Yuan, W. Feng, J. Hong, Q. Zheng, J. Shuai, Y. Ge, p38MAPK and ERK promote nitric oxide production in cultured human retinal pigmented epithelial cells induced by high concentration glucose, Nitric Oxide 20 (2009) 9-15.
43. Y. Zhong, J. Li, Y. Chen, J.J.Wang, R. Ratan, S.X. Zhang, Activation of endoplasmic reticulum stress by hyperglycemia is essential for Müller cell-derived inflammatory cytokine production in diabetes, Diabetes 61 (2012) 492-504.
44. R. Roskoski Jr., ERK1/2 MAP kinases: structure, function, and regulation, Pharmacol Res 66 (2012) 105-143.
45. M.S. Hayden, S. Ghosh, Shared principles in NF-κB signaling, Cell 132 (2008) 344-362.
46. L. Zheng, C. Szabo, T.S. Kern, Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB, Diabetes 53 (2004) 2960-2967.
47. G. Romeo, W.H. Liu, V. Asnaghi, T.S. Kern, M. Lorenzi, Activation of nuclear factorkappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes, Diabetes 51 (2002) 2241-2248.